Drug Trial Radar · NCT03324113
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Oct 17, 2017
Primary completion
Nov 18, 2022
Study completion Dec 26, 2022
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Objective: * To evaluate tolerability and safety of SAR408701 when administered as a single agent according to the investigational medicinal product (IMP) related dose limiting toxicities (DLTs) to determine the recommended dose (RD) of SAR408701 in Japanese patients with advanced malignant solid tumors. Secondary Objectives: * To characterize the overall safety profile of SAR408701 monotherapy. * To characterize the pharmacokinetic (PK) profile of SAR408701 and its metabolites. * To evaluate the pharmacodynamic (PDy) effect of SAR408701 on levels of circulating carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for main dose escalation part. * To assess preliminary efficacy according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria and other indicators of antitumor activity. * To assess the potential immunogenicity of SAR408701.
Conditions
- Neoplasm Malignant
Interventions
SAR408701Drug
Pharmaceutical form: solution for infusion Route of administration: intravenous
dexamethasoneDrug
Pharmaceutical form: solution for eye drop Route of administration: eye drop
naphazolineDrug
Pharmaceutical form: solution for eye drop Route of administration: eye drop
diphenhydramineDrug
Pharmaceutical form: tablet Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- IMP-related dose limiting toxicities (DLT)Time frame: 4 weeks, Dose escalation q3w part: 3 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 3920002
Nagoya, Aichi-ken, Japan
Investigational Site Number : 3920003
Kashiwa-shi, Chiba, Japan
Investigational Site Number : 3920001
Sunto-gun, Shizuoka, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.